The Alzheimer Society Research Portal connects researchers with Canadians looking to participate in research studies. On this website, find active studies that you can participate in to help advance research on dementia.
In the past, frailty and dementia were treated as distinct entities; however, it is now recognized that they share a complex relationship. As a result, there is an urgent need for the joint investigation of frailty and dementia. Our survey aims to bring together perspectives from stakeholders worldwide who share an interest in frailty and dementia. We are collecting data over the next several months, via various promotional "waves." Once we reach adequate participation and thematic saturation, we anticipate that data analysis and knowledge dissemination will take approximately six months.
This study evaluates an at-home, digital cognitive screening tool for older adults experiencing memory changes across the dementia continuum. Participants will complete a brief series of engaging, online brain games and surveys to determine the tool's accuracy compared to traditional clinical assessments. The goal of this study is to provide accessible, patient-friendly monitoring of brain health that reduces the need for clinic travel and lowers barriers to early detection of dementia.
You are eligible to participate if you:
Are 50 years of age or older
Either have healthy cognition or are experiencing noticeable memory or thinking changes (Subjective Cognitive Decline), or have a clinical diagnosis of Mild Cognitive Impairment (MCI) or dementia.
Have access to a computer, laptop, or tablet with a reliable internet connection.
Are able to provide informed consent, or have a legally authorized Substitute Decision Maker (SDM) who can provide consent on your behalf.
Have adequate vision and motor skills to view a screen and tap or click to respond to prompts (such as a choice reaction time task), using glasses or standard aids if necessary.
Are able to read and communicate in English.
Do not have comorbid psychiatric conditions that interfere with cognitive function Do not have a history of brain injury or neurodevelopmental disorders
The goal of this study is to investigate whether very small doses of a drug called levetiracetam (LEV) may reduce abnormal brain signaling in the brain in individuals who are at an increased risk for developing Alzheimer's Disease. Only participants who show the abnormal brain signaling on a functional MRI (fMRI) scan of the brain will be enrolled in the study. Enrolled participants will receive 4 weeks of treatment with LEV and 4 weeks of treatment with placebo (a sugar pill). The study involves cognitive testing, genetic testing, bloodwork, ECGs, questionnaires and several brain imaging scans.
• Are between 55-85 years of age
• Have one or more of these risk factors for Alzheimer's disease (AD):
- A parent or sibling with AD *and* concerns about your own memory
- Two copies of the APOE e4 gene
- A positive AD biomarker result
• Get normal scores on tests of thinking and memory (will be done as part of the study)
• Are able to undergo brain MRI scans
• Are fluent in English
• Are able to attend study visits at Toronto Western Hospital
• Show increased brain signaling during the screening fMRI scan (Note: We anticipate that most people who sign up for the study will NOT show the increased brain activity levels required to qualify for the study treatment)
ML-007C-MA-221 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ML-007C-MA in male and female participants aged 55 to 90 years with hallucinations and delusions associated with Alzheimer's Disease Psychosis (ADP).
The primary objective is to evaluate the efficacy of ML-007C-MA compared with placebo for the treatment of hallucinations and delusions associated with ADP as measured by the Neuropsychiatric Inventory-Clinician (NPI-C): Hallucinations and Delusions (H+D) score.
Male or female participants aged 55 to 90 years of age
Must have a study partner
Presence of psychotic symptoms for at least 2 months before Screening.
The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment [MCI] to mild dementia due to AD).
Male or female participants aged 50 years of age to 90.
Must have a study partner
Participant- and/or Informant-reported history of cognitive decline with gradual onset and progression over the last 1 year before screening
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.
Male or female participants aged 55 years of age to 90.
Must have a study partner
History of agitation due to AD.
McMaster University is conducting a study on the effects of brain stimulation in individuals aged 50 and older with dementia or memory loss. The research focuses on using repetitive transcranial magnetic stimulation (rTMS), a noninvasive technique that delivers magnetic pulses to the brain, to enhance cognitive function and balance. The goal is to extend the positive effects of brain stimulation in improving cognition and balance in individuals with dementia.
1.) Diagnosed with Dementia and/or memory loss by a clinician
2.) Exhibit adequate oral communication skills and cognitive function
3.) Walk or stand with or without personnel or assistive devices
4.) Individuals must be greater than or equal to 50 years of age
This study explores how adult day programs affect the lives of people living with dementia and their caregivers across several Canadian regions. Over time, we gather information about health, well-being, daily experiences, and quality of life of people living with dementia who attend day program and their caregivers. We also aim to learn about day programs themselves, such as their activities, staffing, challenges, and successes. By combining surveys, interviews, and focus groups, our program of research aims to understand what makes day programs helpful, where challenges exist, and how day program can better support families, and people who use them.
You are eligible to participate if you:
• Are an older adult living with dementia who attends or does not attend a day program
• You are a family/friend caregiver of someone living with dementia who attends or does not attend a day program
• Live in one of the participating regions (Ontario, Winnipeg MB, Calgary AB, or Interior BC)
• Are able to take part in a conversation or complete surveys, with support if needed
This study aims to evaluate the acceptance and usability of the GuardIO Family Care app, a mobile application designed to support community safety for individuals living with dementia or mild cognitive impairment and their care partners. The study also aims to analyze mobility patterns collected from the app to explore how mobility data can contribute to the early detection of cognitive impairment. The findings will help improve app design, inform care strategies, and support early intervention efforts for individuals living with dementia or MCI.
You are eligible to participate if you:
Are 18 years of age or older
Are living with mild cognitive impairment (MCI) or dementia, or are a care partner of someone with MCI or dementia
Are able to use a smartphone or tablet with the GuardIO app
Are willing to participate in the study activities, including using the app, completing questionnaires, and attending an optional focus group
Can understand and communicate in English (or another supported language, if applicable)
Follow us: